Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era

British Journal of Haematology

Volumn 171, Issue 4, 2015, Pages 530-538

  Diefenbach, Catherine S ^a   Li, Hailun ^b   Hong, Fangxin ^b   Gordon, Leo I ^c   Fisher, Richard I ^d   Bartlett, Nancy L ^e   Crump, Michael ^f   Gascoyne, Randy D ^g   Wagner, Henry ^h   Stiff, Patrick J ⁱ   Cheson, Bruce D ^j   Stewart, Douglas A ^k   Kahl, Brad S ^l   Friedberg, Jonathan W ^m   Blum, Kristie A ⁿ   Habermann, Thomas M ^o   Tuscano, Joseph M ^p   Hoppe, Richard T ^q   Horning, Sandra J ^r   Advani, Ranjana H ^q  

^a NEW YORK UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h PENN STATE CANCER INSTITUTE   (United States)

ⁱ LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^j GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^k TOM BAKER CANCER CENTRE   (Canada)

^l UNIVERSITY OF WISCONSIN MADISON   (United States)

^m UNIVERSITY OF ROCHESTER   (United States)

ⁿ OHIO STATE UNIVERSITY   (United States)

^o MAYO CLINIC   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q STANFORD UNIVERSITY   (United States)

^r GENENTECH INC   (United States)

more..

Author keywords

ABVD; Hodgkin lymphoma; International Prognostic Score; Prognostic score; Stanford V

Indexed keywords

HEMOGLOBIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINBLASTINE; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; CALIBRATION; CANCER PROGNOSIS; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; FAILURE FREE SURVIVAL; FEMALE; FREEDOM FROM PROGRESSION; HEMOGLOBIN BLOOD LEVEL; HODGKIN DISEASE; HUMAN; INTERMEDIATE RISK PATIENT; INTERNATIONAL PROGNOSTIC SCORE 3; INTERNATIONAL PROGNOSTIC SCORE 7; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; VALIDATION STUDY; AGE; AREA UNDER THE CURVE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; EVALUATION STUDY; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY (TOPIC); PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SAMPLE SIZE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BLEOMYCIN; CLINICAL TRIALS, PHASE III AS TOPIC; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; HODGKIN DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MECHLORETHAMINE; MULTICENTER STUDIES AS TOPIC; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SAMPLE SIZE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; VINBLASTINE; VINCRISTINE;

EID: 84945444823     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13634     Document Type: Article

References (36)

1. Advani, R.H., Chen, H., Habermann, T.M., Morrison, V.A., Weller, E.A., Fisher, R.I., Peterson, B.A., Gascoyne, R.D. & Horning, S.J.; Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; Southwest Oncology Group. (2010) Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). British Journal of Haematology, 151, 143-151.
2. Akaike, H. (1974) A new look at the statistical model identification. IEEE Transactions on Automatic Control, 19, 716-723.
3. American Cancer Society (2013) Cancer Facts and Figures 2013. American Cancer Society, Atlanta, GA. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf
4. Arai, S., Fanale, M., Devos, S., Engert, A., Illidge, T., Borchmann, P., Younes, A., Morschhauser, F., McMillan, A. & Horning, S.J. (2013) Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leukaemia & Lymphoma, 54, 2531-2533.
5. Barrington, S.F., Mikhaeel, N.G., Kostakoglu, L., Meignan, M., Hutchings, M., Mueller, S.P., Schwartz, L.H., Zucca, E., Fisher, R.I., Trotman, J., Hoekstra, O.S., Hicks, R.J., O'Doherty, M.J., Hustinx, R., Biggi, A. & Cheson, B.D. (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology, 32, 3048-3058.
6. Biggi, A., Gallamini, A., Chauvie, S., Hutchings, M., Kostakoglu, L., Gregianin, M., Meignan, M., Malkowski, B., Hofman, M.S. & Barrington, S.F. (2013) International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. Journal of Nuclear Medicine, 54, 683-690.
7. Cheson, B.D., Fisher, R.I., Barrington, S.F., Cavalli, F., Schwartz, L.H., Zucca, E., Lister, T.A., Alliance, A.L. & Lymphoma, G.; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. Journal of Clinical Oncology, 32, 3059-3068.
8. Cook, N.R. & Ridker, P.M. (2009) Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Annals of Internal Medicine, 150, 795-802.
9. Cox, D.R. & Oakes, D. (1984) Analysis of Survival Data. Chapman & Hall, New York. ISBN 041224490X.
10. Eich, H.T., Diehl, V., Gorgen, H., Pabst, T., Markova, J., Debus, J., Ho, A., Dorken, B., Rank, A., Grosu, A.L., Wiegel, T., Karstens, J.H., Greil, R., Willich, N., Schmidberger, H., Dohner, H., Borchmann, P., Muller-Hermelink, H.K., Muller, R.P. & Engert, A. (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. Journal of Clinical Oncology, 28, 4199-4206.
11. Engert, A., Ballova, V., Haverkamp, H., Pfistner, B., Josting, A., Duhmke, E., Muller-Hermelink, K. & Diehl, V.; German Hodgkin's Study Group. (2005) Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology, 23, 5052-5060.
12. Engert, A., Plutschow, A., Eich, H.T., Lohri, A., Dorken, B., Borchmann, P., Berger, B., Greil, R., Willborn, K.C., Wilhelm, M., Debus, J., Eble, M.J., Sokler, M., Ho, A., Rank, A., Ganser, A., Trumper, L., Bokemeyer, C., Kirchner, H., Schubert, J., Kral, Z., Fuchs, M., Muller-Hermelink, H.K., Muller, R.P. & Diehl, V. (2010) Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. New England Journal of Medicine, 363, 640-652.
13. Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., Zijlstra, J., Kral, Z., Fuchs, M., Hallek, M., Kanz, L., Dohner, H., Dorken, B., Engel, N., Topp, M., Klutmann, S., Amthauer, H., Bockisch, A., Kluge, R., Kratochwil, C., Schober, O., Greil, R., Andreesen, R., Kneba, M., Pfreundschuh, M., Stein, H., Eich, H.T., Muller, R.P., Dietlein, M., Borchmann, P. & Diehl, V.; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet, 379, 1791-1799.
14. Evens, A.M., Hong, F., Gordon, L.I., Fisher, R.I., Bartlett, N.L., Connors, J.M., Gascoyne, R.D., Wagner, H., Gospodarowicz, M., Cheson, B.D., Stiff, P.J., Advani, R., Miller, T.P., Hoppe, R.T., Kahl, B.S. & Horning, S.J. (2013) The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. British Journal of Haematology, 161, 76-86.
15. Federico, M., Luminari, S., Iannitto, E., Polimeno, G., Marcheselli, L., Montanini, A., La Sala, A., Merli, F., Stelitano, C., Pozzi, S., Scalone, R., Di Renzo, N., Musto, P., Baldini, L., Cervetti, G., Angrilli, F., Mazza, P., Brugiatelli, M. & Gobbi, P.G.; HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. (2009a) ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology, 27, 805-811.
16. Federico, M., Bellei, M., Marcheselli, L., Luminari, S., Lopez-Guillermo, A., Vitolo, U., Pro, B., Pileri, S., Pulsoni, A., Soubeyran, P., Cortelazzo, S., Martinelli, G., Martelli, M., Rigacci, L., Arcaini, L., Di Raimondo, F., Merli, F., Sabattini, E., McLaughlin, P. & Solal-Celigny, P. (2009b) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. Journal of Clinical Oncology, 27, 4555-4562.
17. Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., Biggi, A., Vitolo, U., Stelitano, C., Sancetta, R., Trentin, L., Luminari, S., Iannitto, E., Viviani, S., Pierri, I. & Levis, A. (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. Journal of Clinical Oncology, 25, 3746-3752.
18. Gonen, M. & Heller, G. (2005) Concordance probability and discriminative power of proportional hazards regression. Biometrika, 92, 965-970.
19. Gordon, L.I., Hong, F., Fisher, R.I., Bartlett, N.L., Connors, J.M., Gascoyne, R.D., Wagner, H., Stiff, P.J., Cheson, B.D., Gospodarowicz, M., Advani, R., Kahl, B.S., Friedberg, J.W., Blum, K.A., Habermann, T.M., Tuscano, J.M., Hoppe, R.T. & Horning, S.J. (2013) Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). Journal of Clinical Oncology, 31, 684-691.
20. Hasenclever, D. & Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. New England Journal of Medicine, 339, 1506-1514.
21. Heagerty, P.J. & Zheng, Y. (2005) Survival model predictive accuracy and ROC curves. Biometrics, 61, 92-105.
22. Hutchings, M., Mikhaeel, N.G., Fields, P.A., Nunan, T. & Timothy, A.R. (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Annals of Oncology, 16, 1160-1168.
23. Kamper, P., Bendix, K., Hamilton-Dutoit, S., Honore, B., Nyengaard, J.R. & d'Amore, F. (2011) Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica, 96, 269-276.
24. Kanakry, J.A., Li, H., Gellert, L.L., Lemas, M.V., Hsieh, W.S., Hong, F., Tan, K.L., Gascoyne, R.D., Gordon, L.I., Fisher, R.I., Bartlett, N.L., Stiff, P., Cheson, B.D., Advani, R., Miller, T.P., Kahl, B.S., Horning, S.J. & Ambinder, R.F. (2013) Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood, 121, 3547-3553.
25. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
26. Landgren, O., Algernon, C., Axdorph, U., Nilsson, B., Wedelin, C., Porwit-MacDonald, A., Grimfors, G. & Bjorkholm, M. (2003) Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica, 88, 438-444.
27. Moccia, A.A., Donaldson, J., Chhanabhai, M., Hoskins, P.J., Klasa, R.J., Savage, K.J., Shenkier, T.N., Slack, G.W., Skinnider, B., Gascoyne, R.D., Connors, J.M. & Sehn, L.H. (2012) International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. Journal of Clinical Oncology, 30, 3383-3388.
28. Scott, D.W., Chan, F.C., Hong, F., Rogic, S., Tan, K.L., Meissner, B., Ben-Neriah, S., Boyle, M., Kridel, R., Telenius, A., Woolcock, B.W., Farinha, P., Fisher, R.I., Rimsza, L.M., Bartlett, N.L., Cheson, B.D., Shepherd, L.E., Advani, R.H., Connors, J.M., Kahl, B.S., Gordon, L.I., Horning, S.J., Steidl, C. & Gascoyne, R.D. (2013) Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. Journal of Clinical Oncology, 31, 692-700.
29. Sehn, L.H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K.J., Shenkier, T., Sutherland, J., Gascoyne, R.D. & Connors, J.M. (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109, 1857-1861.
30. Steidl, C., Lee, T., Shah, S.P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S.J., Iqbal, J., Weisenburger, D.D., Bast, M.A., Rosenwald, A., Muller-Hermelink, H.K., Rimsza, L.M., Campo, E., Delabie, J., Braziel, R.M., Cook, J.R., Tubbs, R.R., Jaffe, E.S., Lenz, G., Connors, J.M., Staudt, L.M., Chan, W.C. & Gascoyne, R.D. (2010) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. The New England Journal of Medicine, 362, 875-885.
31. Steidl, C., Diepstra, A., Lee, T., Chan, F.C., Farinha, P., Tan, K., Telenius, A., Barclay, L., Shah, S.P., Connors, J.M., van den Berg, A. & Gascoyne, R.D. (2012) Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood, 120, 3530-3540.
32. Straus, D.J., Portlock, C.S., Qin, J., Myers, J., Zelenetz, A.D., Moskowitz, C., Noy, A., Goy, A. & Yahalom, J. (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood, 104, 3483-3489.
33. Tan, K.L., Scott, D.W., Hong, F., Kahl, B.S., Fisher, R.I., Bartlett, N.L., Advani, R.H., Buckstein, R., Rimsza, L.M., Connors, J.M., Steidl, C., Gordon, L.I., Horning, S.J. & Gascoyne, R.D. (2012) Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood, 120, 3280-3287.
34. Viviani, S., Zinzani, P.L., Rambaldi, A., Brusamolino, E., Levis, A., Bonfante, V., Vitolo, U., Pulsoni, A., Liberati, A.M., Specchia, G., Valagussa, P., Rossi, A., Zaja, F., Pogliani, E.M., Pregno, P., Gotti, M., Gallamini, A., Rota Scalabrini, D., Bonadonna, G. & Gianni, A.M.; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. (2011) ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. New England Journal of Medicine, 365, 203-212.
35. Younes, A., Gopal, A.K., Smith, S.E., Ansell, S.M., Rosenblatt, J.D., Savage, K.J., Ramchandren, R., Bartlett, N.L., Cheson, B.D., de Vos, S., Forero-Torres, A., Moskowitz, C.H., Connors, J.M., Engert, A., Larsen, E.K., Kennedy, D.A., Sievers, E.L. & Chen, R. (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. Journal of Clinical Oncology, 30, 2183-2189.
36. Zhou, Z., Sehn, L.H., Rademaker, A.W., Gordon, L.I., Lacasce, A.S., Crosby-Thompson, A., Vanderplas, A., Zelenetz, A.D., Abel, G.A., Rodriguez, M.A., Nademanee, A., Kaminski, M.S., Czuczman, M.S., Millenson, M., Niland, J., Gascoyne, R.D., Connors, J.M., Friedberg, J.W. & Winter, J.N. (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood, 123, 837-842.